{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-23-001534","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2023-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.485873+00:00","generated_at":"2026-06-07T21:47:48.416468+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vivani Medical terminates named executive officer Scott Dunbar in subsidiary workforce reduction","bullets":["Scott Dunbar terminated without cause effective Nov 20, 2023 as part of Cortigent workforce reduction.","Dunbar was a named executive officer in 2023 proxy and former Acting CEO of predecessor Second Sight Medical.","Severance includes ~$70,000 cash payment and COBRA premium reimbursement for up to six months.","Company intends to enter a separation and release agreement with Dunbar."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-23-001534","json":"https://secwatch.observer/filing/0001753926-23-001534.json","markdown":"https://secwatch.observer/filing/0001753926-23-001534.md","text":"https://secwatch.observer/filing/0001753926-23-001534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623001534/0001753926-23-001534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623001534/g083867_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:47:48.416468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e1d45f58e","claim":"Scott Dunbar departed as Named Executive Officer at Vivani Medical, Inc..","evidence_excerpt":"the Company terminated without cause the employment of Scott Dunbar, a named executive officer in the Company’s 2023 proxy statement and former Acting Chief Executive Officer of the Company’s predecessor, Second Sight Medical Products, Inc., effective as of November 20, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392623001534/0001753926-23-001534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Named Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}